Androgen deprivation therapy (ADT) is the standard of care for patients with metastatic
prostate cancer (mPC). However, nearly all patients with mPC progress to castration …

Given prostate cancer is driven, in part, by its responsiveness to androgens, treatments
historically employ methods for their removal from circulation. Approaches as crude as …

Aims Despite impressive survival benefits from new agents to treat metastasized prostate
cancer (PCa), progressive drug resistance hinders long-term response and restricts the …

Androgen deprivation therapy (ADT) is the standard care for advanced prostate cancer
(PCa) patients. Unfortunately, although tumors respond well initially, they enter dormancy …

Simple Summary An advanced prostate cancer research study known as HERO compared
the ability of the medications relugolix and leuprolide to lower testosterone. The goal was to …

The natural compound, amygdalin, is notably popular with prostate cancer patients as an
alternative or complementary treatment option. However, knowledge about its mode of …

ABSTRACT Introduction: Prostate cancer (PCa) is the most common cancer in elderly males.
Androgen deprivation therapy (ADT) is still the cornerstone of initial treatment; however, the …

Secondary resistant mutations in cancer cells arise in response to certain small molecule
inhibitors. These mutations inevitably cause recurrence and often progression to a more …

Various novel androgen receptor (AR) targeting drugs have been developed recently and
have shown beneficial effects on survival in patients with metastatic castration-resistant …

Prostate cancer is the most common cancer in men in the Western world. One-third of the
patients with prostate cancer will develop resistance to hormonal therapy and progress into …